Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ enriched peripheral blood stem cells with mononuclear cell addback
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ enriched peripheral blood stem cells with mononuclear cell addback is an investigational cellular therapy designed for allogeneic hematopoietic stem cell transplantation (alloSCT). The process involves mobilizing peripheral blood stem cells (PBSCs) using G-CSF, followed by positive selection for CD34+ cells to deplete T-cells and reduce the risk of acute graft-versus-host disease (aGVHD). To mitigate the risks of delayed immune reconstitution and opportunistic infections associated with pure CD34+ selection, a fixed, low dose of peripheral blood mononuclear cells (PBMNCs) — specifically 2×10⁵ CD3+ T cells/kg — is added back to the graft. This approach aims to balance the prevention of GVHD with the promotion of rapid engraftment and robust immune recovery. It has been evaluated in pediatric and adult patients with various hematologic malignancies and non-malignant conditions like sickle cell disease.
- Other names
- CD34+ enriched PBSC with MNC addbackCD34+ enrichment with mononuclear cell addbackCD34+ enriched peripheral blood stem cells with T-cell addback
Beyond the preview
Go deeper on CD34+ enriched peripheral blood stem cells with mononuclear cell addback.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ enriched peripheral blood stem cells with mononuclear cell addback.